Management of Arthralgias Associated with Aromatase Inhibitor Therapy
نویسندگان
چکیده
منابع مشابه
Management of arthralgias associated with aromatase inhibitor therapy
For the upfront adjuvant therapy of postmenopausal estrogen receptor-positive breast cancer, the third-generation aromatase inhibitors (AIS) have shown a more favourable overall risk-benefit profile than has tamoxifen. Benefits of the ais include less frequent gynecologic, cerebrovascular, and thromboembolic adverse events; greater disease-free survival; and lower tumour recurrence. Although ap...
متن کاملEruptive keloids associated with aromatase inhibitor therapy
INTRODUCTION Eruptive keloids are rarely described in the literature and are typically reported in association with a systemic disease. Because reports of eruptive keloids are sparse, the pathophysiology of eruptive keloids remains to be clearly explained. We report a case of a 77-year-old woman who had extensive eruptive keloids while taking letrozole for hormone receptorepositive infiltrating...
متن کاملTai chi for well-being of breast cancer survivors with aromatase inhibitor-associated arthralgias: a feasibility study.
CONTEXT Arthralgia is common and debilitating for a significant proportion of breast cancer survivors (BCSs) and leads to poor adherence to aromatase inhibitors (AIs). Despite increased recognition of the negative impact of arthralgia on function and the poor adherence that results, very few interventions have been developed to target this side effect. OBJECTIVE This study aimed to determine ...
متن کاملAppraising adjuvant aromatase inhibitor therapy.
Tamoxifen, once the gold standard adjuvant endocrine therapy for early breast cancer, is being challenged by third-generation aromatase inhibitors (AIs) that have demonstrated improved disease-free survival in a variety of adjuvant settings for early breast cancer. Tamoxifen and AIs have different safety profiles, which should allow physicians to begin to individualize treatment based on a pati...
متن کاملAromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management.
The introduction of aromatase inhibitor (AI) therapy for the adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer has led to a significant change in the management of the disease. AIs are slightly more efficacious and initially appeared to have a better toxicity profile compared to the previous gold standard, tamoxifen. However, increased use of AIs in the com...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Oncology
سال: 2007
ISSN: 1718-7729
DOI: 10.3747/co.2007.152